Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).

Detalles Bibliográficos
Autores principales: Le Bourgeois, Amandine, Coste-Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Béné, Marie C., Chevallier, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441592/
https://www.ncbi.nlm.nih.gov/pubmed/34519770
http://dx.doi.org/10.1001/jamanetworkopen.2021.26344
_version_ 1783752899909648384
author Le Bourgeois, Amandine
Coste-Burel, Marianne
Guillaume, Thierry
Peterlin, Pierre
Garnier, Alice
Béné, Marie C.
Chevallier, Patrice
author_facet Le Bourgeois, Amandine
Coste-Burel, Marianne
Guillaume, Thierry
Peterlin, Pierre
Garnier, Alice
Béné, Marie C.
Chevallier, Patrice
author_sort Le Bourgeois, Amandine
collection PubMed
description This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).
format Online
Article
Text
id pubmed-8441592
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-84415922021-10-04 Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Le Bourgeois, Amandine Coste-Burel, Marianne Guillaume, Thierry Peterlin, Pierre Garnier, Alice Béné, Marie C. Chevallier, Patrice JAMA Netw Open Research Letter This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT). American Medical Association 2021-09-14 /pmc/articles/PMC8441592/ /pubmed/34519770 http://dx.doi.org/10.1001/jamanetworkopen.2021.26344 Text en Copyright 2021 Le Bourgeois A et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Le Bourgeois, Amandine
Coste-Burel, Marianne
Guillaume, Thierry
Peterlin, Pierre
Garnier, Alice
Béné, Marie C.
Chevallier, Patrice
Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
title Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
title_full Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
title_fullStr Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
title_full_unstemmed Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
title_short Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
title_sort safety and antibody response after 1 and 2 doses of bnt162b2 mrna vaccine in recipients of allogeneic hematopoietic stem cell transplant
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441592/
https://www.ncbi.nlm.nih.gov/pubmed/34519770
http://dx.doi.org/10.1001/jamanetworkopen.2021.26344
work_keys_str_mv AT lebourgeoisamandine safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant
AT costeburelmarianne safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant
AT guillaumethierry safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant
AT peterlinpierre safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant
AT garnieralice safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant
AT benemariec safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant
AT chevallierpatrice safetyandantibodyresponseafter1and2dosesofbnt162b2mrnavaccineinrecipientsofallogeneichematopoieticstemcelltransplant

Ejemplares similares